Historical Valuation
SH PHARMA (02607) is now in the Fair zone, suggesting that its current forward PE ratio of 16.83 is considered Fairly compared with the five-year average of 12.18. The fair price of SH PHARMA (02607) is between -- to -- according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：11.87
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
SH PHARMA (02607) has a current Price-to-Book (P/B) ratio of 0.51. Compared to its 3-year average P/B ratio of 0.95 , the current P/B ratio is approximately -45.80% higher. Relative to its 5-year average P/B ratio of 1.01, the current P/B ratio is about -49.38% higher. SH PHARMA (02607) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of 4.99%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of 3.88% , the current FCF yield is about -100.00% lower.
Performance Decomposition
AI Analysis
1Y
3Y
5Y
Market capitalization of 02607 increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of 02607 in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is 02607 currently overvalued or undervalued?
SH PHARMA (02607) is now in the Fair zone, suggesting that its current forward PE ratio of 16.83 is considered Fairly compared with the five-year average of 12.18. The fair price of SH PHARMA (02607) is between to according to relative valuation methord.
What is SH PHARMA (02607) fair value?
02607's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of SH PHARMA (02607) is between to according to relative valuation methord.
How does 02607's valuation metrics compare to the industry average?
The average P/S ratio for 02607's competitors is , providing a benchmark for relative valuation. SH PHARMA Corp (02607) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for SH PHARMA (02607) as of Jan 15 2026?
As of Jan 15 2026, SH PHARMA (02607) has a P/B ratio of 0.51. This indicates that the market values 02607 at 0.51 times its book value.
What is the current FCF Yield for SH PHARMA (02607) as of Jan 15 2026?
As of Jan 15 2026, SH PHARMA (02607) has a FCF Yield of 0.00%. This means that for every dollar of SH PHARMA’s market capitalization, the company generates 0.00 cents in free cash flow.
What is the current Forward P/E ratio for SH PHARMA (02607) as of Jan 15 2026?
As of Jan 15 2026, SH PHARMA (02607) has a Forward P/E ratio of 16.83. This means the market is willing to pay $16.83 for every dollar of SH PHARMA’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for SH PHARMA (02607) as of Jan 15 2026?
As of Jan 15 2026, SH PHARMA (02607) has a Forward P/S ratio of 0.00. This means the market is valuing 02607 at $0.00 for every dollar of expected revenue over the next 12 months.